Table 3.
Scoring system | Without neoadjuvant chemotherapy (group A) | Before neoadjuvant chemotherapy (group B1) | After neoadjuvant chemotherapy (group B2) | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
n | Median time (months) | 95% CI | 3 years (%) | P-value | n | Median time (months) | 95% CI | 3 years (%) | P-value | n | Median time (months) | 95% CI | 3 years (%) | P-value | |
Nordlinger | 150 | 16 | 12–20 | 40 | 0.028a | 101 | 13 | 9–17 | 36 | 0.458a | 101 | 13 | 9–17 | 36 | 0.173a |
0–2 | 87 | 18 | 0–43 | 46 | 37 | 13 | 5–22 | 38 | 47 | 14 | 7–23 | 40 | |||
3–4 | 59 | 15 | 11–19 | 34 | 60 | 13 | 6–20 | 36 | 53 | 12 | 7–17 | 33 | |||
5–6 | 4 | 4 | 0–12 | 0 | 4 | 3 | 0–9 | 0 | 1 | – | – | – | |||
Fong | 150 | 16 | 12–20 | 40 | <0.001 | 101 | 13 | 9–17 | 36 | 0.603 | 101 | 13 | 9–17 | 36 | 0.096 |
0–2 | 123 | 21 | 3–39 | 47 | 54 | 13 | 3–23 | 38 | 70 | 14 | 6–22 | 39 | |||
3–5 | 27 | 10 | 8–12 | 11 | 47 | 12 | 7–17 | 34 | 31 | 7 | 3–11 | 29 | |||
Nagashima | 193 | 14 | 11–17 | 35 | 0.001a | 159 | 9 | 7–11 | 26 | 0.030a | 159 | 9 | 7–11 | 26 | 0.001a |
0–1 | 112 | 18 | 10–26 | 44 | 61 | 13 | 6–20 | 32 | 72 | 14 | 8–20 | 34 | |||
2–3 | 77 | 10 | 7–13 | 24 | 94 | 7 | 5–9 | 22 | 84 | 6 | 5–7 | 18 | |||
≥4 | 4 | 11 | 5–17 | 0 | 4 | 6 | – | 25 | 3 | 6 | – | – | |||
Konopke | 145 | 16 | 11–21 | 41 | 0.002 | 69 | 21 | 3–39 | 45 | 0.354 | 69 | 21 | 3–39 | 45 | 0.663 |
0 | 91 | 37 | 12–61 | 51 | 13 | 41 | – | 61 | 15 | 41 | 0–83 | 59 | |||
1 | 47 | 14 | 10–18 | 29 | 38 | 21 | 0–44 | 45 | 46 | 20 | 6–34 | 41 | |||
≥2 | 7 | 9 | 0–22 | 0 | 18 | 6 | 0–14 | 32 | 8 | 6 | 0–14 | 38 |
CI confidence interval, CRS clinical risk score
aAs a result of the small numbers of patients, CRS subgroup 3 (CRS ≥4) was pooled together with subgroup 2 (CRS 2–3)